Gregory Verdine

Biography

Dr. Verdine has made important contributions in the translation of bench science to the bedside.  He has founded or co-founded a number of successful biotechnology companies, including Enanta Pharmaceuticals (Nasdaq ENTA), Gloucester Pharmaceuticals (acquired by Celgene), Tokai Pharmaceuticals (Nasdaq TKAI), WaVe Life Sciences (Nasdaq WVE), Eleven Biotherapeutics (Nasdaq EBIO), Warp Drive Bio, Aileron Therapeutics, and FogPharma.  To date, these companies have succeeded in gaining FDA approval for two drugs, romidepsin (Gloucester/Celgene) and paritaprevir (Enanta/AbbVie).  He has also worked in the venture capital industry as a Venture Partner with Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ventures, and as a Special Advisor to Texas Pacific Group. He co-founded and served as the founding President of the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy, for which he continues to serve as Director. 

Research Interest

Our research has led to the invention of new and powerful approaches for the discovery of unconventional bioactive ligands termed "synthetic biologics" that have proven effective at addressing therapeutic targets previously considered "undruggable." Verdine and coworkers have elucidated the mechanism by which DNA methyltransferases catalyze epigenetic modification of the genome, as well as the structural basis for sequence specific DNA recognition by NF-κB and NFAT, master regulators of acute phase and immune responses and organ development.